Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride

Nephrology

Volumn 16, Issue 8, 2011, Pages 743-750

  Chen, Jin Bor ^a   Chiang, Shou Shan ^b   Chen, Hung Chun ^c   Obayashi, Seiichi ^d   Nagasawa, Masaki ^e   Hexham, J Mark ^f   Balfour, Alison ^f   Junge, Guido ^f   Akiba, Takashi ^g   Fukagawa, Masafumi ^h  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d Kinashi Obayashi Hospital   (Japan)

^e JA Shinonoi General Hospital   (Japan)

^f NOVARTIS PHARMA AG   (Switzerland)

^g TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^h TOKAI UNIVERSITY   (Japan)

Author keywords

Chronic kidney disease; End stage kidney disease; Hemodialysis; Hyperphosphatemia; SBR759

Indexed keywords

IRON; IRON DERIVATIVE; PHOSPHATE BINDING AGENT; SBR 759; SEVELAMER; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ABNORMAL FECES; ADULT; AGED; ARTICLE; ASIAN; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONNECTIVE TISSUE DISEASE; CONSTIPATION; DIABETES MELLITUS; DIARRHEA; DISEASE CONTROL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INTOXICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; HYPERTENSION; INFECTION; INFESTATION; IRON THERAPY; JAPANESE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NAUSEA; OPEN STUDY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TAIWANESE; TRANSFERRIN SATURATION; UPPER ABDOMINAL PAIN; VASCULAR DISEASE; VOMITING;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CALCIUM; CHELATING AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; FERRIC COMPOUNDS; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHOSPHATES; POLYAMINES; RENAL DIALYSIS; STARCH; TAIWAN; TREATMENT OUTCOME;

EID: 84055221986     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2011.01509.x     Document Type: Article

References (23)

1. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol. Dial. Transplant. 2000;15(7):1014-21. (Pubitemid 30410374)
2. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. 2000;342(20):1478-83. (Pubitemid 30318271)
3. Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N. Engl. J. Med. 2010;362(14):1312-24.
4. Young EW, Akiba T, Albert JM et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am. J. Kidney Dis. 2004;44(5 Suppl 2):34):34-8.
5. Mohammed I, Hutchison AJ. Oral phosphate binders for the management of serum phosphate levels in dialysis patients. J. Ren. Care 2009;35(Suppl 1): 65):65-70.
6. Raggi P, Vukicevic S, Moyses RM, Wesseling K, Spiegel DM. Ten-year experience with sevelamer and calcium salts as phosphate binders. Clin. J. Am. Soc. Nephrol. 2010;5(Suppl 1): S31-40.
7. Tonelli M, Wiebe N, Culleton B et al. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol. Dial. Transplant. 2007;22(10):2856-66. (Pubitemid 350093462)
8. Mohammed IA, Hutchison AJ. Phosphate binding therapy in dialysis patients: Focus on lanthanum carbonate. Ther. Clin. Risk Manag. 2008;4(5):887-93.
9. Nikolov IG, Joki N, Vicca S et al. Tissue accumulation of lanthanum as compared to aluminum in rats with chronic renal failure - possible harmful effects after long-term exposure. Nephron Exp. Nephrol. 2010;115:e112-21.
10. Hutchison AJ, Barnett ME, Krause R, Siami GA. Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis. Clin. Nephrol. 2009;71(3):286-95.
11. Block GA, Brillhart SL, Persky SM. Efficacy and safety of SBR759, a new iron-based phosphate binder. Kidney Int. 2010;77(10):897-903.
12. Wei M, Taskapan H, Esbaei K, Jassal SV, Bargman JM, Oreopoulos DG. K/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: Can we achieve them? Int. Urol. Nephrol. 2006;38(3-4):739-43. (Pubitemid 46336034)
13. Renagal tablets (sevelamer hydrochloride) 400 & 800 mg: Highlights of prescribing information. [Cited 13 Apr. 2010.] Available from URL: http://www.genzymeclinicalresearch.com/pdf/renagel-pi.pdf
14. Braun J, Asmus HG, Holzer H et al. Long-term comparison of a calcium-free phosphate binder and calcium carbonate - phosphorus metabolism and cardiovascular calcification. Clin. Nephrol. 2004;62(2):104-15. (Pubitemid 39162762)
15. K/DOQI, National Kidney Foundation: Clinical Practice Guidelines for Hemodialysis Adequacy. 2000. Update 2000; Guideline 6: Target Iron Level. [Cited 13 April 2010.] Available from URL: http://wwwkidneyorg/PROFESSIONALS/kdoqi/ guidelines-updates/doqi-uptochtml
16. Suzuki M, Kurihara S, Osono E et al. Effects of PB-94 (Sevelamer hydrochloride), a phosphate binder, on the treatment of hyperphosphatemia in hemodialysis patients - A randomized, open label, dose titration study of PB-04 versus Caltan Tab. 500 (calcium carbonate). Kidney Dial. 2003;55(2):383-400.
17. Hervas JG, Prados D, Cerezo S. Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: A comparison with calcium acetate. Kidney Int. Suppl. 2003;85:S69-72. (Pubitemid 36605867)
18. London GM, Marchais SJ, Guerin AP, Boutouyrie P, Metivier F, de Vernejoul MC. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J. Am. Soc. Nephrol. 2008;19(9):1827-35.
19. Uhlig K, Berns JS, Kestenbaum B et al. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am. J. Kidney Dis. 2010;55(5):773-99.
20. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl. 2009;113:S1-130.
21. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am. J. Kidney Dis. 2003;42:S1-170.
22. Ogata H, Koiwa F, Shishido K, Kinugasa E. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: Alternative approach for optimal mineral management. Ther. Apher. Dial. 2005;9(1):11-15. (Pubitemid 40393318)
23. Delmez J, Block G, Robertson J et al. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin. Nephrol. 2007;68(6):386-91. (Pubitemid 350258767)